The first patient with relapsed/refractory multiple myeloma has been treated with the investigational therapy bb21217, according to the clinical-stage company bluebird bio. The treatment candidate…
Newly-diagnosed multiple myeloma patients who are not eligible for a stem cell transplant reduce the risk of disease progression or death by half when Darzalex (daratumumab)…
Kite Pharma has submitted an investigational new drug application to the U.S. Food and Drug Administration that would pave the way toward clinical trials of its…
Combining the proteasome inhibitor Kyprolis (carfilzomib) with dexamethasone is beneficial for adult patients with multiple myeloma who have received…
Myeloma patients who received a single dose of the investigational therapy CLR 131 in an ongoing Phase 1 clinical trial have reached a median overall…
Newly diagnosed multiple myeloma patients who use Revlimid (lenalidomide) as a maintenance therapy after a stem cell transplant live significantly longer than those receiving a placebo…
Merck has suspended patient enrollment in two Phase 3 clinical trials, KEYNOTE-183 and KEYNOTE-185, testing Keytruda (pembrolizumab) in combination with other therapies in patients…
Many patients with blood cancers, such as myeloma, go into remission after receiving a stem-cell transplant. However, there are still many patients (about one-third) who relapse, a condition…
Results from a clinical trial support the use of a specific combination drug induction therapy over another three-drug treatment in multiple myeloma patients who are eligible…
Results from an ongoing clinical trial supports the use of upfront autologous stem cell transplantation (ASCT) to treat multiple myeloma patients age 65 or younger.